Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

[1]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[2]  Sascha Steinbiss,et al.  FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context , 2011, Journal of Clinical Bioinformatics.

[3]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[4]  J. Lanchbury,et al.  A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  J. Squire,et al.  PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer , 2011, BJU international.

[6]  P. Pandolfi,et al.  Haplo‐insufficiency: a driving force in cancer , 2011, The Journal of pathology.

[7]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[8]  H. Huland,et al.  Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients , 2011, Journal of Cancer Research and Clinical Oncology.

[9]  C. Le Page,et al.  Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-κB signalling pathway and prognostic significance in prostate cancer , 2010, British Journal of Cancer.

[10]  Hartwig Huland,et al.  Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.

[11]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[12]  K. Pantel,et al.  Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications , 2010, BMC Cancer.

[13]  G. Sauter,et al.  Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer , 2009, Clinical Cancer Research.

[14]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[15]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[16]  M. Teitell,et al.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.

[17]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[18]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[19]  G. Hampton,et al.  Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. , 2009, Neoplasia.

[20]  R. Cardiff,et al.  Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. , 2009, Differentiation; research in biological diversity.

[21]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[22]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[23]  K. Nielsen,et al.  Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.

[24]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[25]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[26]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[27]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[28]  Yang Xu,et al.  Gain of Function of p53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways , 2007, Cell cycle.

[29]  D. Troyer,et al.  Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation , 2007, Clinical Cancer Research.

[30]  D. Theodorescu,et al.  The role of PTEN in prostate cancer cell tropism to the bone micro-environment. , 2007, Carcinogenesis.

[31]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[32]  Tom Misteli,et al.  Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression , 2007, Cell.

[33]  A. Ziaee,et al.  Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.

[34]  S. Taneja,et al.  Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression , 2006, Cancer.

[35]  Paulo A. S. Nuin,et al.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. , 2006, Cancer genetics and cytogenetics.

[36]  M. Gleave,et al.  Loss of PTEN is associated with progression to androgen independence , 2006, The Prostate.

[37]  H. Stoop,et al.  The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.

[38]  W. Sellers,et al.  Akt-regulated pathways in prostate cancer , 2005, Oncogene.

[39]  John K Field,et al.  Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[41]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[42]  L. Bubendorf,et al.  Expression patterns of potential therapeutic targets in prostate cancer , 2005, International journal of cancer.

[43]  S. Horvath,et al.  Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer , 2004, Clinical Cancer Research.

[44]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[45]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[46]  M. Mareel,et al.  The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness , 2001, The Journal of cell biology.

[47]  M. Ittmann,et al.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[49]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[50]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[52]  H. Frierson,et al.  PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate , 1998, Oncogene.

[53]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[54]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[55]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[56]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[57]  M. Wigler,et al.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[59]  M. Emi,et al.  Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer , 1996, Genes, chromosomes & cancer.

[60]  T. Glover,et al.  Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. , 1996, Cancer research.

[61]  H. Huland,et al.  Immunohistochemical detection of p53 protein in human prostatic cancer. , 1994, The Journal of urology.

[62]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.